Platelet function in male diabetics with and without macrovascular complications

Tóth, L; Szénási, P; Jámbor, G; Kammerer, L; Romics, L

doi:10.1016/0168-8227(92)90018-m

Cited by 9 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The finding of increased aggregation response by ADP in diabetic patients is in aggrement with the finding reported previously [7,11,13,14]. Altough it was reported previously that there was a possitive correlation between the age and platelet aggregation responses [15,16].…”

Section: Openly Accessible Atsupporting

confidence: 87%

See 1 more Smart Citation

Platelet aggregation responses in type 2 diabetic patients

Güven¹,

Yılmaz²,

Aydın³

et al. 2010

Health

View full text Add to dashboard Cite

Diabetes mellitus (DM) is associated with platelet dysfunction. In diabetic patients, alterations in platelet functions, especially increased platelet agregation, have been suggested to cause increasing in cardiovascular morbidity and mortality or in accelaretion of athersclerotic process. In this study, we aimed to investigate the platelet aggregation response alterations and the effects of DM duration, HbA1c, treatment options among the patients with Type 2 DM. Fortyfive patients (case group; 21 male, 24 female) with Type 2 DM and forty-eight healthy individuals (control group; 22 male, 26 female) were included in this study. Platelet aggregation was determinated with Chorono-log 500 (USA) named device by using Chorono-log/ADP, Chorono-log/ collagen and Chorono-log/epinephrine kits. ADP-induced platelet aggregation was significantly higher in the case group compared with control group (p < 0.05). Epinephrine induced platelet aggregation were significant in negatively correlation with the diabetes duration (P < 0.05). Platelet aggregation responses did not differ according to their treatment type (sulphonylurea or insulin) was statistically insignificiant among the case groups (p > 0.05). In conclusion, our findings supported that type 2 diabetes may interfere with platelet functions without any relationship age, gender, the treatment types and the regulation levels. These findings supports that existence potential new factors or mechanism affecting platelet agregation. The subject requires more detailed studies in the future

show abstract

Section: Openly Accessible Atsupporting

confidence: 87%

“…Patient with type 2 DM had altered platelet functions and increased platelet aggregation responses with agonists [11,12]. Table 3.…”

Section: Discussionmentioning

confidence: 99%

Platelet aggregation responses in type 2 diabetic patients

Güven¹,

Yılmaz²,

Aydın³

et al. 2010

Health

View full text Add to dashboard Cite

show abstract

“…The study population comprised men without prevalent CVD. Results from previous studies on diabetes mellitus and platelet aggregation within this research area has to some degree been discordant with our observations, since some studies reported higher platelet aggregation in persons with diabetes mellitus [12,7,9,11,8,10], while others found no differences in platelet aggregation [19,20,16,35,17,18,36]. The largest previous study comprised 77 persons with diabetes mellitus, while 8 out of 13 studies included less than 40 persons with diabetes mellitus [16,7,17,9,[18][19][20]10].…”

Section: Discussionsupporting

confidence: 63%

“…Previous studies of platelet aggregation in diabetes mellitus have used the cumbersome classical gold standard LTA method for platelet function testing [26,25], which explains why prior studies merely tested few agonists, most often ADP, and typically at only few concentrations [12,7,9,11,8,10,19,20,16,35,17,18,36]. In contrast, our 96-well platelet aggregometry assay enables concomitant testing of multiple relevant platelet agonists at various concentrations with a small volume of blood [24,27].…”

Section: Discussionmentioning

confidence: 99%

“…Among studies of platelet function in persons with diabetes mellitus, several studies reported an increased platelet aggregation response when tested in vitro [7][8][9][10][11][12]. These observations have led to experimental studies concerning putative effects of high glucose concentrations on platelet pathways and ideas about specific platelet related targets for treatment of atherothrombosis in diabetes mellitus [13][14][15].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Platelet aggregation is not altered among men with diabetes mellitus

et al. 2019

View full text Add to dashboard Cite

Aims: Platelets are pivotal in arterial thrombosis, and platelet hyperresponsiveness may contribute to the increased incidence of cardiovascular events in diabetes mellitus. Consequently, we hypothesized that increased in vitro platelet aggregation responses exist in men with diabetes mellitus. Methods: The Danish Cardiovascular Screening Trial (DANCAVAS) is a communitybased cardiovascular screening trial including men aged 65-74 years. Platelet aggregation was tested using 96-well light transmission aggregometry with thrombin receptor-activating peptide (TRAP), adenosine diphosphate, collagen type-1, arachidonic acid, and proteaseactivated receptor-4 in three concentrations. Further, cardiovascular risk factors and coronary artery calcification (CAC), estimated by CT-scans and ankle-brachial index were obtained. Results: Included were 720 men aged 65-74 years, 110 with diabetes mellitus. Overall, there was no difference in platelet aggregation among men with versus without diabetes mellitus when adjusting for, or excluding platelet inhibitor treatment and men with established cardiovascular disease (CVD). This was true for all agonists, e.g. 10 µM TRAP-induced platelet aggregation of median 69 % (IQR 53-75) versus 70% (IQR 60-76) in men with versus without diabetes mellitus. Platelet aggregation did not correlate with HbA1c, or CAC. Men with diabetes mellitus displayed higher CAC, median 257 Agatston Units (IQR 74-1141) versus median 111 Agatston Units (IQR 6-420) in the remaining individuals, p<0.0001.

show abstract

Urinary albumin excretion is correlated to fibrinogen levels and protein S activity in patients with type 1 diabetes mellitus without overt diabetic nephropathy

Lengyel

Vörös

Tóth

et al. 2004

Wien Klin Wochenschr

View full text Add to dashboard Cite

The aim of the study was to test the hypothesis that in diabetic patients without overt nephropathy there may be a correlation between the activity of natural anticoagulant proteins and glomerular dysfunction. Assays for functional activity of proteins S and C, measurements of urinary albumin excretion, lipid parameters and haemoglobin A1c were performed in 91 patients with type 1 diabetes mellitus and 85 patients with type 2. Patients with type 1 diabetes and microalbuminuria had significantly higher mean age (44.1 +/- 10.9 vs. 37.9 +/- 12.7 years; p<0.05), fibrinogen level (3.75 +/- 1.0 vs. 3.21 +/- 0.8 g/l; p<0.01), protein S activity (92.3 +/- 17.6 vs. 84.5 +/- 15.5%; p<0.05) and higher prevalence of retinopathy (p<0.01) and macrovascular disease (p<0.01) than those with normoalbuminuria. Albumin excretion was significantly correlated to age (r=0.25, p<0.05), fibrinogen level (r=0.39, p<0.01), protein S activity (r=0.27; p<0.05), total cholesterol (r=0.23; p<0.05), apoprotein B (r=0.22; p<0.05), retinopathy (r=0.33; p<0.01) and macrovascular disease (r=0.33; p<0.01). Patients with type 2 diabetes mellitus and microalbuminuria had significantly higher apoprotein B levels (1.17 +/- 0.3 vs. 1.06 +/- 1.2 mg/dl; p<0.05) than those with normoalbuminuria, and apoprotein B was significantly correlated to albumin excretion (r=0.22; p<0.05). In a multivariate model of type 1 diabetes mellitus with fibrinogen, protein S and C activity, cholesterol, triglycerides, haemoglobin A1c, retinopathy, and macrovascular disease as independent parameters (r=0.53; p<0.003), there was significant independent correlation of fibrinogen (beta=0.28; p<0.01), protein S activity (beta=0.27; p<0.05) and retinopathy (beta=0.21; p<0.01) with albumin excretion. We conclude that in type 1 diabetes, relative elevation of fibrinogen level and protein S activity appear in the early stages of development of diabetic nephropathy, and may be related to the pathogenesis of diabetic kidney disease.

show abstract

Platelet function in male diabetics with and without macrovascular complications

Cited by 9 publications

References 35 publications

Platelet aggregation responses in type 2 diabetic patients

Platelet aggregation responses in type 2 diabetic patients

Platelet aggregation is not altered among men with diabetes mellitus

Urinary albumin excretion is correlated to fibrinogen levels and protein S activity in patients with type 1 diabetes mellitus without overt diabetic nephropathy

Contact Info

Product

Resources

About